본문 바로가기
KERD
논문KCI 등재

SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene

김수현|박호영|송창선|전현정|Hisham Yasmin
대한면역학회 (The Korean Association of Immunologists)|2021.10|Immune Network|제21권 제5호|pp. 1-14|DOI 10.4110/in.2021.21.e32

0

조회

0

다운로드

1

인용

0

참고문헌

키워드

SARS-CoV-2Spike geneReceptor binding motif (RBM)COVID-19 deltaT478K

초록

Over two hundred twenty-eight million cases of coronavirus disease 2019 (COVID-19) in the world have been reported until the 21st of September 2021 after the first rise in December 2019. The virus caused the disease called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Over 4 million deaths blame COVID-19 during the last one year and 8 months in the world. Currently, four SARS-CoV-2 variants of concern are mainly focused by pandemic studies with limited experiments to translate the infectivity and pathogenicity of each variant. The SARS-CoV-2 α, β, γ, and δ variant of concern was originated from United Kingdom, South Africa, Brazil/Japan, and India, respectively. The classification of SARS-CoV-2 variant is based on the mutation in spike (S) gene on the envelop of SARS-CoV-2. This review describes four SARS-CoV-2 α, β, γ, and δ variants of concern including SARS-CoV-2 ε, ζ, η, ι, κ, and B.1.617.3 variants of interest and alert. Recently, SARS-CoV-2 δ variant prevails over different countries that have 3 unique mutation sites: E156del/R158G in the N-terminal domain and T478K in a crucial receptor binding domain. A particular mutation in the functional domain of the S gene is probably associated with the infectivity and pathogenesis of the SARS-CoV-2 variant.

Abstract

Over two hundred twenty-eight million cases of coronavirus disease 2019 (COVID-19) in the world have been reported until the 21st of September 2021 after the first rise in December 2019. The virus caused the disease called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Over 4 million deaths blame COVID-19 during the last one year and 8 months in the world. Currently, four SARS-CoV-2 variants of concern are mainly focused by pandemic studies with limited experiments to translate the infectivity and pathogenicity of each variant. The SARS-CoV-2 α, β, γ, and δ variant of concern was originated from United Kingdom, South Africa, Brazil/Japan, and India, respectively. The classification of SARS-CoV-2 variant is based on the mutation in spike (S) gene on the envelop of SARS-CoV-2. This review describes four SARS-CoV-2 α, β, γ, and δ variants of concern including SARS-CoV-2 ε, ζ, η, ι, κ, and B.1.617.3 variants of interest and alert. Recently, SARS-CoV-2 δ variant prevails over different countries that have 3 unique mutation sites: E156del/R158G in the N-terminal domain and T478K in a crucial receptor binding domain. A particular mutation in the functional domain of the S gene is probably associated with the infectivity and pathogenesis of the SARS-CoV-2 variant.

참고문헌 (63)

  1. Brown CM, "Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings-Barnstable County, Massachusetts, July 2021", MMWR Morb Mortal Wkly Rep, 70, pp.1059~1062 (2021)
  2. Dagpunar J, "Interim estimates of increased transmissibility, growth rate, and reproduction number of the COVID-19 B.1.617.2 variant of concern in the United Kingdom", medRxiv, doi:10.1101, 2021 (2021)
  3. Liu Y, "The reproductive number of the delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus", J Travel Med, pp.taab124~ (2021)
  4. Li B, "Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 delta variant", medRxiv. doi:10.1101, 2021 (2021)
  5. Ong SWX, "Clinical and virological features of SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7(alpha), B.1.315 (beta), and B.1.617.2 (delta)", Clin Infect Dis, pp.ciab721~ (2021)
  6. Riemersma KK, "Shedding of infectious SARS-CoV-2 despite vaccination", medRxiv. doi: 10.1101, 2021 (2021)
  7. Shi Q, "Rapid global spread of the SARS-CoV-2 delta(B. 1. 617. 2)variant : spatiotemporal variation and public health impact", Zoonoses, 1, pp.1~6 (2021)
  8. Lopez Bernal J, "Effectiveness of COVID-19 vaccines against the B. 1. 617. 2(delta)variant", N Engl J Med, 385, pp.585~594 (2021)
  9. Sheikh A, "SARS-CoV-2 delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness", Lancet, 397, pp.2461~2462 (2021)
  10. Li W, "Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus", Nature, 426, pp.450~454 (2003)
  11. Chen Y, "Structure analysis of the receptor binding of 2019-nCoV", Biochem Biophys Res Commun, 525, pp.135~140 (2020)
  12. Lan J, "Structure of the SARSCoV-2 spike receptor-binding domain bound to the ACE2 receptor", Nature, 581, pp.215~220 (2020)
  13. Shang J, "Structural basis of receptor recognition by SARS-CoV-2", Nature, 581, pp.221~224 (2020)
  14. Song W, "Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2", PLoS Pathog, 14, pp.e1007236~ (2018)
  15. Wrapp D, "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation", Science, 367, pp.1260~1263 (2020)
  16. Yan R, "Structural basis for the recognition of SARS-CoV-2 by fulllength human ACE2", Science, 367, pp.1444~1448 (2020)
  17. Yuan M, "A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV", Science, 368, pp.630~633 (2020)
  18. Yuan Y, "Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains", Nat Commun, 8, pp.15092~ (2017)
  19. Creech CB, "SARS-CoV-2 vaccines", JAMA, 325, pp.1318~1320 (2021)
  20. 홍재우, "Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target", Immune Network, 21(1), pp.1~17 (2021), 대한면역학회[DOI]
  21. Sinae Kim, "The Progression of SARS Coronavirus 2 (SARS-CoV2): Mutation in the Receptor Binding Domain of Spike Gene", Immune Network, 20(5), pp.1~11 (2020), 대한면역학회[DOI]
  22. Martínez-Flores D, "SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants", Front Immunol, 12, pp.701501~ (2021)
  23. Kim B, "The interleukin-1α precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines", Front Immunol, 4, pp.391~ (2013)
  24. Areum Kwak, "Intracellular interleukin (IL)-1 family cytokine processing enzyme", Archives of Pharmacal Research, 39(11), pp.1556~1564 (2016), 대한약학회
  25. Lee S, "Proinsulin shares a motif with interleukin-1α(IL-1α)and induces inflammatory cytokine via interleukin-1 receptor 1", J Biol Chem, 291, pp.14620~14627 (2016)
  26. Li F, "Structure of SARS coronavirus spike receptor-binding domain complexed with receptor", Science, 309, pp.1864~1868 (2005)
  27. Wang Q, "Structural and functional basis of SARS-CoV-2 entry by using human ACE2", Cell, 181, pp.894~904.e9 (2020)
  28. Chen RE, "In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains", Nature, 596, pp.103~108 (2021)
  29. Taylor PC, "Neutralizing monoclonal antibodies for treatment of COVID-19", Nat Rev Immunol, 21, pp.382~393 (2021)
  30. Gao Q, "Development of an inactivated vaccine candidate for SARS-CoV-2", Science, 369, pp.77~81 (2020)
  31. Corbett KS, "SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness", Nature, 586, pp.567~571 (2020)
  32. Folegatti PM, "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 : a preliminary report of a phase 1", 2, single-blind, randomised controlled trial, 2020, pp.396, 467~478
  33. Frater J, "Safety and immunogenicity of the ChAdOx1 nCoV-19(AZD1222)vaccine against SARS-CoV-2 in HIV infection : a single-arm substudy of a phase 2", 3 clinical trial, 2021, pp.8, e474~e485
  34. Hassan AO, "A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARSCoV-2", Cell, 183, pp.169~184.e13 (2020)
  35. Keech C, "Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine", N Engl J Med, 383, pp.2320~2332 (2020)
  36. Wang J, "New strategy for COVID-19 vaccination : targeting the receptor-binding domain of the SARSCoV-2 spike protein", Cell Mol Immunol, 18, pp.243~244 (2021)
  37. Yang J, "A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity", Nature, 586, pp.572~577 (2020)
  38. Arif TB, "The 501.V2 and B.1.1.7 variants of coronavirus disease 2019 (COVID-19): a new time-bomb in the making?", Infect Control Hosp Epidemiol, 2021, pp.1~2 (2021)
  39. Davies NG, "Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England", Science, 372, pp.eabg3055~ (2021)
  40. Wu K, "mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants", bioRxiv. doi: 10.1101, 2021 (2021)
  41. Barrett CT, "Effect of clinical isolate or cleavage site mutations in the SARS-CoV-2 spike protein on protein stability, cleavage, and cell-cell fusion", J Biol Chem, 297, pp.100902~ (2021)
  42. Belouzard S, "Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites", Proc Natl Acad Sci U S A, 106, pp.5871~5876 (2009)
  43. Simmons G, "Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry", Proc Natl Acad Sci U S A, 102, pp.11876~11881 (2005)
  44. Simmons G, "Proteolytic activation of the SARS-coronavirus spike protein : cutting enzymes at the cutting edge of antiviral research", Antiviral Res, 100, pp.605~614 (2013)
  45. Claro IM, "Local transmission of SARS-CoV-2 lineage B. 1. 1. 7, Brazil, December 2020", Emerg Infect Dis, 27, pp.970~972 (2021)
  46. Gidari A, "Cross-neutralization of SARS-CoV-2 B. 1. 1. 7 and P. 1 variants in vaccinated, convalescent and P. 1 infected", J Infect, 83, pp.467~472 (2021)
  47. Wang P, "Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization", bioRxiv. doi:10.1101, 2021 (2021)
  48. Yadav PD, "Isolation and characterization of the new SARS-CoV-2 variant in travellers from the United Kingdom to India: VUI202012", 01 of the B.1.1.7 lineage, 2021, pp.28, taab009~
  49. Leung K, "Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020", Euro Surveill, 26 (2021)[DOI]
  50. Planas D, "Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization", Nature, 596, pp.276~280 (2021)
  51. Chen LL, "Impact of SARS-CoV-2 variant-associated RBD mutations on the susceptibility to serum antibodies elicited by COVID-19 infection or vaccination", Clin Infect Dis, pp.ciab656~ (2021)
  52. Deng X, "Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation", medRxiv. doi:10.1101, 2021 (2021)
  53. Martin Webb L, "Identification of and surveillance for the SARS-CoV-2 variants B. 1. 427 and B. 1. 429-Colorado, January-March 2021", MMWR Morb Mortal Wkly Rep, 70, pp.717~718 (2021)
  54. Ozer EA, "Coincident rapid expansion of two SARS-CoV-2 lineages with enhanced infectivity in Nigeria", medRxiv. doi: 10.1101, 2021 (2021)
  55. Annavajhala MK, "Emergence and expansion of the SARS-CoV-2 variant B.1.526 identified in New York", medRxiv . doi: 10.1101, 2021 (2021)
  56. Collier DA, "Sensitivity of SARS-CoV-2 B. 1. 1. 7 to mRNA vaccine-elicited antibodies", Nature, 593, pp.136~141 (2021)
  57. Emary KR, "Efficacy of ChAdOx1 nCoV-19(AZD1222)vaccine against SARS-CoV-2 variant of concern 202012", 01(B. 1. 1. 7) : an exploratory analysis of a randomised controlled trial, 2021, pp.397, 1351~1362
  58. Wang P, "Antibody resistance of SARS-CoV-2 variants B. 1. 351 and B. 1. 1. 7", Nature, 593, pp.130~135 (2021)
  59. Jangra S, "SARS-CoV-2 spike E484K mutation reduces antibody neutralisation", Lancet Microbe, 2, pp.e283~e284 (2021)
  60. Greaney AJ, "Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies", Cell Host Microbe, 29, pp.463~476.e6 (2021)
  61. McCallum M, "SARS-CoV-2 immune evasion by the B. 1. 427", B. 1. 429 variant of concern, 2021, pp.373, 648~654
  62. Elbe S, "Data, disease and diplomacy : GISAID's innovative contribution to global health", Glob Chall, 1, pp.33~46 (2017)
  63. Liu C, "Reduced neutralization of SARS-CoV-2 B. 1. 617 by vaccine and convalescent serum", Cell, 184, pp.4220~4236.e13 (2021)

관련 논문AI추천

SARS-CoV-2 Variants of Concern최준용, Davey M. Smith연세대학교의과대학 · Yonsei Medical Journal2021 · 제62권 제11호SARS-CoV-2 Omicron Mutation Is Faster than the Chase: Multiple Mutations on Spike/ACE2 Interaction Residues김수현, 송창선, 전현정, Choi Yang Kyu, Kim Byoungguk, Kim Sinae, Kim Sung-Han, Kim Yong-Gil, Lee Youngmin, Netea Mihai, Nguyen Tam T., Park Ho-Young, Shin Kyeong-Cheol, Song Eun Young, Taitt Afeisha S., Yeom Su Cheong, Yum Hokee대한면역학회 · Immune Network2021 · 제21권 제6호SARS-CoV-2 Omicron Variant of Concern: Everything You Wanted to Know about Omicron but Were Afraid to Ask최준용, Davey M. Smith, Dong Hoon Shin연세대학교의과대학 · Yonsei Medical Journal2022 · 제63권 제11호Differential Impact of Spike Protein Mutations on SARS-CoV-2 Infectivity and Immune Evasion: Insights from Delta and Kappa VariantsBae Sojung, Kim Tae-Hun, Myoung Jinjong한국미생물·생명공학회 · Journal of Microbiology and Biotechnology2024 · 제34권 제12호Understanding SARS-CoV-2 Variants and Safety Countermeasures for the Fight against Omicron김명류, 홍복실동북아학술저널연합 · International Journal of Crisis & Safety2022 · 제7권 제1호The Progression of SARS Coronavirus 2 (SARS-CoV2): Mutation in the Receptor Binding Domain of Spike Gene강린우, 김수현, 신경철, 이영민, Edward D. Chan, Heijun Kim, Hokee Yum, Hyun Jhung Jhun, Jaewoo Hong, Jihyeong Hwang, Jong Ho Lee, Kwang Ha Yoo, Liping Yu, Saerok Shim, Sinae Kim, Siyoung Lee, Su Cheong Yeom, Suyoung Bae, Tam T. Nguyen, Tania Azam, Yeo-Ok Choi, Yong-Dae Kim대한면역학회 · Immune Network2020 · 제20권 제5호

이 간행물의 다른 논문 (5건)

Inflammasome-Dependent Peroxiredoxin 2 Secretion Induces the Classical Complement Pathway Activation이현숙, 신전수, 곽만섭, 박철호pp. 1-16Induction of Unique STAT Heterodimers by IL-21 Provokes IL-1RI Expression on CD8 + T Cells, Resulting in Enhanced IL-1β Dependent Effector Function김희영, 이원우, 김동현pp. 1-19Induction of Anti-Aquaporin 5 Autoantibody Production by Immunization with a Peptide Derived from the Aquaporin of Prevotella melaninogenica Leads to Reduced Salivary Flow in Mice이용희, 정준호, 이아름, 권성훈, 전수민, 김홍희, 주소연, 정수한, 황시원, 노진성, 유덕균, YoungnimChoipp. 1-16Hepatitis B virus X Protein Promotes Liver Cancer Progression through Autophagy Induction in Response to TLR4 Stimulation이지수, 김미정, 김지영, 이기영, 전은영, 손주희pp. 1-17IL-17 and IL-17C Signaling Protects the Intestinal Epithelium against Diisopropyl Fluorophosphate Exposure in an Acute Model of Gulf War Veterans' IllnessesPatterson Kristen M., Vajdic Tyler G., Martinez Gustavo J., Feller Axel G., Reynolds Joseph M.pp. 1-16
원문 보기